Literature DB >> 23685026

A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.

Georgia Levidou1, Marina Siakantaris, Theodora Papadaki, Evangelia Papadavid, Theodoros P Vassilakopoulos, Maria K Angelopoulou, Leonidas Marinos, Vassiliki Nikolaou, Aphroditi Economidi, Christina Antoniou, Efstratios Patsouris, Penelope Korkolopoulou.   

Abstract

BACKGROUND: Although the expression pattern of phosphorylated (p)-mTOR pathway components has attracted scientific interest in several neoplasms, to our knowledge, there is no published information regarding its significance in mycosis fungoides (MF).
OBJECTIVE: We sought to perform a comprehensive simultaneous assessment of key members of AKT/mTOR pathway along with p-extracellular signal-regulated kinase (ERK), NOTCH1, and p-STAT3 in patients with MF.
METHODS: In all, 54 skin biopsy specimens (21 tumors, 30 plaques, and 3 folliculotropic MF) from 50 patients with MF were analyzed immunohistochemically for p-mTOR, its upstream p-AKT, its downstream effectors p-p70S6K and p-4E-BP1, and for p-ERK1/2, NOTCH1, and p-STAT3.
RESULTS: p-mTOR was coexpressed with p-p70S6K in 67.3% of lesions, but coexpression with other molecules was less common. p-p70S6K and marginally NOTCH1 displayed higher H-scores in tumors than in plaques. Significant correlations were recorded between p-ERK and p-4E-BP1, as well as between NOTCH1 and p-p70S6K or p-4E-BP1. NOTCH1, p-4E-BP1, and p-p70S6K expression were associated with advanced stage. In survival analysis simultaneous overexpression of p-AKT and p-p70S6K, along with p-4E-BP1 positivity, adversely affected cancer-specific, disease-free, and progression-free survival in advanced-stage cases. LIMITATIONS: A limitation may be the small number of cases included in our investigation, precluding multivariate survival analysis.
CONCLUSIONS: Activation of AKT/mTOR pathway in MF appears to be correlated with NOTCH1, p-ERK, and p-STAT3 and is implicated in the acquisition of a more aggressive phenotype. The combination of p-AKT, p-p70S6K, and p-4E-BP1 emerges as a significant potential prognostic marker in patients with advanced stage.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  4E-BP1; AKT; CSS; DFS; ERK; MF; NOTCH1; PFS; STAT3; cancer-specific survival; disease-free survival; extracellular signal-regulated kinase; mTOR; mycosis fungoides; p; p70S6K; phosphorylated; progression-free survival

Mesh:

Substances:

Year:  2013        PMID: 23685026     DOI: 10.1016/j.jaad.2013.04.027

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

Authors:  Elias A El-Habr; Georgia Levidou; Eleni-Andriana Trigka; Joanna Sakalidou; Christina Piperi; Ilenia Chatziandreou; Anastasia Spyropoulou; Rigas Soldatos; Georgia Tomara; Kalliopi Petraki; Vassilis Samaras; Athanasios Zisakis; Vassilis Varsos; George Vrettakos; Efstathios Boviatsis; Efstratios Patsouris; Angelica A Saetta; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

2.  Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma.

Authors:  Wasakorn Kittipongdaja; Xuesong Wu; Justine Garner; Xiping Liu; Steven M Komas; Sam T Hwang; Stefan M Schieke
Journal:  J Invest Dermatol       Date:  2015-04-21       Impact factor: 8.551

Review 3.  Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.

Authors:  Cristina Cristofoletti; Antonella Bresin; Martina Fioretti; Giandomenico Russo; Maria Grazia Narducci
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

4.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

5.  Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Authors:  Eleftheria Lakiotaki; Georgia Levidou; Maria K Angelopoulou; Christos Adamopoulos; Gerassimos Pangalis; George Rassidakis; Theodoros Vassilakopoulos; Gabriella Gainaru; Pagona Flevari; Sotirios Sachanas; Angelica A Saetta; Athanasia Sepsa; Maria Moschogiannis; Christina Kalpadakis; Nikolaos Tsesmetzis; Vassilios Milionis; Ilenia Chatziandreou; Irene Thymara; Panayiotis Panayiotidis; Maria Dimopoulou; Eleni Plata; Konstantinos Konstantopoulos; Efstratios Patsouris; Christina Piperi; Penelope Korkolopoulou
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 6.  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.

Authors:  Tomonori Oka; Tomomitsu Miyagaki
Journal:  Front Med (Lausanne)       Date:  2019-05-29

7.  Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Vassiliki Mpakou; Aris Spathis; Periklis G Foukas; Maria Dalamaga; Vasiliki Pappa; Evangelia Papadavid
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

8.  Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer.

Authors:  Dimitrios S Kanakoglou; Andromachi Pampalou; Dimitrios M Vrachnos; Eleni A Karatrasoglou; Dionysia N Zouki; Emmanouil Dimonitsas; Alexia Klonou; Georgia Kokla; Varvara Theologi; Errieta Christofidou; Stratigoula Sakellariou; Eleftheria Lakiotaki; Christina Piperi; Penelope Korkolopoulou
Journal:  Int J Oncol       Date:  2022-02-16       Impact factor: 5.650

9.  Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Berta Casar; Dalia de la Fuente-Vivas; Rocío García-Gómez; Kyriaki Lampadaki; Vasiliki Pappa; Evangelia Papadavid
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.